Virobay

2006 - Founded as an anti-viral drug discovery and development company

2007 - Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2007 – In-licensed cathepsin protease inhibitor assets; including VBY-129, a selective cathepsin S inhibitor which completed phase 1 clinical development for psoriasis

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple orally bioavailable development candidates are poised for Phase I

Learn more